In the preclinical setting our research group is focusing on
optimizing the timing and duration of targeted agents in relation
to the RT
These targeted agents involve the currently used
radiosensitizers, and the more recently developed immunotherapy
agents and agents targeting a specific factor that is involved in
the radiotherapy response.
This research is executed in different models with the focus on
glioblastoma patients. In addition we use also other models to
uncover radiation escape and exploit new treatment strategies (e.g.
breast cancer tumor models). It is our goal that with the knowledge
of this preclinical research we can introduce novel treatment
strategies in the clinic.
In the clinical setting we study MRI based anatomical and
functional characteristics and changes to guide our radiotherapy
treatment delivery for patients with brain metastasis and
glioblatoma. We also study the effect of changes on the dose
coverage of the tumor to optimize the timing of the MRI and how to
develop better radiotherapy treatment strategies to target
Clinical interests: neuro-oncology; patients with primary
brain tumors and brain metastasis.
In our group of preclinical, translational and clinical
researchers we are following the bench to bedside approach and also
bring clinically relevant questions into the lab. It is our goal to
elucidate underlying mechanisms of treatment resistance, study new
treatment strategies and ultimately improve the treatment
outcome of our patients.